Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Operating Expenses: 2017-2024

Historic Operating Expenses for Tonix Pharmaceuticals Holding (TNXP) over the last 8 years, with Dec 2024 value amounting to $146.8 million.

  • Tonix Pharmaceuticals Holding's Operating Expenses rose 97.85% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.2 million, marking a year-over-year decrease of 27.90%. This contributed to the annual value of $146.8 million for FY2024, which is 16.37% up from last year.
  • According to the latest figures from FY2024, Tonix Pharmaceuticals Holding's Operating Expenses is $146.8 million, which was up 16.37% from $126.1 million recorded in FY2023.
  • Tonix Pharmaceuticals Holding's Operating Expenses' 5-year high stood at $146.8 million during FY2024, with a 5-year trough of $50.5 million in FY2020.
  • In the last 3 years, Tonix Pharmaceuticals Holding's Operating Expenses had a median value of $126.1 million in 2023 and averaged $128.3 million.
  • Data for Tonix Pharmaceuticals Holding's Operating Expenses shows a peak YoY soared of 82.76% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Tonix Pharmaceuticals Holding's Operating Expenses stood at $50.5 million in 2020, then skyrocketed by 82.76% to $92.3 million in 2021, then climbed by 21.43% to $112.1 million in 2022, then increased by 12.54% to $126.1 million in 2023, then grew by 16.37% to $146.8 million in 2024.